gsk
TRANSCRIPT
AN ORGANIZATION STUDY
CHAPTER – I
COMPANY PROFILE
BANGALORE INSITUTE OF MANAGEMENT STUDIES Page 1
AN ORGANIZATION STUDY
1.1 INTRODUCTION OF ORGANIZATION
GSK is one of the few pharmaceutical companies researching both medicines and vaccines for
the World Health Organization’s three priority diseases – HIV/AIDS, tuberculosis and malaria,
and are very proud to have developed some of the leading global medicines in these fields.
Headquartered in the UK and with operations based in the US, GSK is one of the industry
leaders, with an estimated seven per cent of the world's pharmaceutical market.
But being a leader brings responsibility. This means that GSK care about the impact that it’s
have on the people and places touched by our mission to improve health around the world.
It also means that GSK must help developing countries where debilitating disease affects
millions of people and access to life-changing medicines and vaccines is a problem. To meet this
challenge, we are committed to providing discount medicines where they are needed the most.
As a company with a firm foundation in science, GSK have a flair for research and a track record
of turning that research into powerful, marketable drugs. Every hour GSK spend more than
£300,000 (US$562,000) to find new medicines.
GSK produce medicines that treat six major disease areas – asthma, virus control, infections,
mental health, diabetes and digestive conditions. In addition, GSK is a leader in the important
area of vaccines and is developing new treatments for cancer.
GSK also market other products, many of which are among the market leaders:
Over-the-counter (OTC) medicines including Gaviscon and Panadol
Dental products such as Aquafresh and Macleans
Smoking control products Nicorette/Niquitin
Nutritional healthcare drinks such as Lucozade, Ribena and Horlicks
BANGALORE INSITUTE OF MANAGEMENT STUDY Page 2
AN ORGANIZATION STUDY
1.2 GSK’S WORLDWIDE MAP
GSK WORLDWIDE
EUROPE
United Kingdom Cyprus Iceland Netherlands Spain
Albania Czech Republic Ireland Norway Sweden
Austria Denmark Italy Poland Switzerland
Armenia Estonia Kazakhstan Portugal Ukraine
Belarus Finland Latvia Romania
Belgium France Lithuania Russia
Bosnia Herzegovina Germany Macedonia Serbia
Bulgaria Greece Malta Slovakia
Croatia Hungary Moldova Slovenia
NORTH AMERICA
BANGALORE INSITUTE OF MANAGEMENT STUDIES Page 3
AN ORGANIZATION STUDY
United States Canada Mexico
CENTRAL AND SOUTH AMERICA
Argentina Costa Rica Honduras Uruguay
Brazil Ecuador Nicaragua Venezuela
Chile El Salvador Panama
Colombia Guatemala Peru
CARIBBEAN
Dominican Republic Jamaica Trinidad
ASIA AND AUSTRALASIA
Australia Hong Kong New Zealand Uzbekistan
Azerbaijan India Pakistan
Bangladesh Japan Sri Lanka
China Korea Taiwan
SOUTHEAST ASIA
Cambodia Malaysia Philippines Thailand
Indonesia Myanmar Singapore Vietnam
AFRICA
Algeria Morocco South Africa
Kenya Nigeria
MIDDLE EAST
Egypt Israel Saudi Arabia Turkey
BANGALORE INSITUTE OF MANAGEMENT STUDIES Page 4
AN ORGANIZATION STUDY
1.3 INTRODUCTION OF THE COMPANY IN INDIA
Established in the year 1924 in India GlaxoSmithKline Pharmaceuticals Ltd. (GSK Rx India) is
one of the oldest pharmaceuticals company and employs over 3500 people. Globally, we are a
USD 42 billion, leading, research-based healthcare and pharmaceutical company. In India, we
are one of the market leaders with a turnover of Rs. 1500 crore and a share of 6.2 per cent*.
The GSK India product portfolio includes prescription medicines and vaccines. Our prescription
medicines range across therapeutic areas such as anti-infectives, dermatology, gynaecology,
diabetes, cardiovascular disease and respiratory diseases. The company is the market leader in
most of the therapeutic categories in which it operates. GSK also offers a range of vaccines, for
the prevention of hepatitis A, hepatitis B, invasive disease caused by H, influenzae, chickenpox,
diphtheria, pertussis, tetanus and others.
With opportunities in India opening up, GSK India is aligning itself with the parent company in
areas such as clinical trials, clinical data management, global pack management, sourcing raw
material and support for business processes including analytics.
GSK’s best-in-class field force, backed by a nation-wide network of stockists, ensures that the
Company’s products are readily available across the nation. GSK has two manufacturing units in
India, located at Nashik and Thane as well as a clinical development centre in Bangalore. The
state of art plant at Nashik makes formulations while bulk drugs are manufactured at Thane.
Being a leader brings responsibility towards the communities in which we operate. At GSK we
have a Corporate Social Responsibility program, that works towards fulfilling basic healthcare,
education and other developmental needs of 15 tribal villages near Nashik. We work with
underprivileged children from the slums of Mumbai, taking care of their developmental and
health needs. GSK also runs an HIV/AIDS helpline - considered to be a pioneering effort in
India that supports those in distress and despair.
GSK is committed to developing new and effective healthcare solutions. The values on which
the group was founded have always inspired growth and will continue to do so in times to come.
BANGALORE INSITUTE OF MANAGEMENT STUDIES Page 5
AN ORGANIZATION STUDY
1.4 GSK AT A GLANCE
GSK mission is to improve the quality of human life by enabling people to do more,
feel better and live longer
GSK are a research-based pharmaceutical company
GSK are committed to tackling the three "priority" diseases identified by the World
Health Organization: HIV/AIDS, tuberculosis and malaria
GSK business employs around 100,000 people in over 100 countries
GSK make almost four billion packs of medicines and healthcare products every year
Over 15,000 people work in GSK research teams to discover new medicines
GSK screen about 65 million compounds every year in our search for new medicines
GSK supply one quarter of the world's vaccines and by the end of February 2008 we
had 24 vaccines in clinical development
January 2008 marked the tenth anniversary of our program to help eliminate lymphatic
filariasis (elephantiasis). During those ten years we donated 750 million albendazole
tablets, reaching over 130 million people
In 2007 we marked 15 years of our Positive Action programme that helps communities
living with HIV/AIDS
In the developing world, we provide certain medicines at preferential prices ensuring
that the poorest can still benefit from our treatments and vaccines
In 2007, our total community investment was valued at £282 million, equivalent to 3.8
per cent of Group total profit before tax
Many of our consumer brands are household names: Ribena, Horlicks, Lucozade,
Aquafresh, Sensodyne, Panadol, Tums, Zovirax.
BANGALORE INSITUTE OF MANAGEMENT STUDIES Page 6
AN ORGANIZATION STUDY
1.5 HISTORY 0F THE COMPANY
GSK company has a rich history that goes back to the early eighteenth century.
1700-1799
1715
Plough Court pharmacy, the forerunner of Allen and Hanburys Ltd, is established in London by Silvanus Bevan.
1800-1849
1830
John K Smith opens his first drugstore in Philadelphia. John's younger brother, George, joins him in 1841 to form John K Smith & Co.
1850-1899
1859
Beecham opens the world's first factory to be built solely for making medicines at St Helens in England.
1865
Mahlon Kline joins Smith and Shoemaker - as John K Smith and Co had become - as a bookkeeper
1873
Joseph Nathan, who left the UK to seek new business opportunities 20 years before, establishes a general trading company at Wellington in New Zealand - Joseph Nathan and Co - the foundation for the Glaxo company to be formed later.
1880
Burroughs Wellcome & Company is established in London by American pharmacists Henry Wellcome and Silas Burroughs, four years after Joseph Nathan opened a London office.
BANGALORE INSITUTE OF MANAGEMENT STUDIES Page 7
AN ORGANIZATION STUDY
1884
Tabloid is registered as a Burroughs Wellcome and Company trademark to describe its compressed tablets.
1885
Thomas Beecham's company acquires headquarters on the corner of Silver Street and Water Street, St Helens, England. Two years later, the company's new factory in St Helens becomes the first in the area to have electricity
1900-1949
1902
The Wellcome Tropical Research Laboratories open
1906
Glaxo is registered by Joseph Nathan and Co as a trademark for dried milk. A Burroughs Wellcome subsidiary is created in New York.
1908
The Glaxo department of Joseph Nathan and Co opens in London and the first "baby book" is published.
1913
Production of Beecham's Pills laxative reaches one million a day.
1919
Alex C Maclean establishes Macleans Ltd, manufacturing own-name products for chemists. Mahlon Kline begins the novel practice of sending pharmaceutical samples through the mail to doctors across the US.
1945
Beecham Group Ltd is established, replacing Beecham Pills Ltd and Beecham Estates Ltd - later known as Beecham Group plc - and incorporates Beecham Research Laboratories.
BANGALORE INSITUTE OF MANAGEMENT STUDIES Page 8
AN ORGANIZATION STUDY
1947
Glaxo Laboratories Ltd absorbs the Joseph Nathan company and becomes the parent company. Glaxo is listed on the London Stock Exchange. New Beecham laboratories are established at Brockham Park in Surrey, England.
1950-1999
1958
Glaxo acquires Allen and Hanburys Ltd.
1959
The Wellcome Foundation acquires Cooper, McDougall and Robertson Ltd, an animal health company founded in 1843.
1970
Burroughs Wellcome Inc moves its production facility from New York to Greenville, North Carolina.
1978
Through the acquisition of Meyer Laboratories Inc, Glaxo's business in the US is started, to become Glaxo Inc from 1980.
1981
The anti-ulcer treatment Zantac (ranitidine) is launched by Glaxo and is to become the world's top-selling medicine by 1986.
1988
SmithKline BioScience Laboratories acquires one of its largest competitors, International Clinical Laboratories, Inc, increasing the company's size by half and establishing SmithKline BioScience Laboratories as the industry leader.
The Nobel Prize for medicine is awarded to George Hitchings and Gertrude Elion, of Burroughs Wellcome Inc, and to Sir James Black, who had worked at the Wellcome Foundation and Smith Kline and French Laboratories, "for their discoveries of important principles for drug treatment."
BANGALORE INSITUTE OF MANAGEMENT STUDIES Page 9
AN ORGANIZATION STUDY
1998
SmithKline Beecham and the World Health Organization announce a collaboration to eliminate lymphatic filariasis (elephantiasis) by the year 2020. The largest pharmaceutical company in Poland is created with the acquisition of Polfa Poznan by Glaxo Wellcome.
2000+
2001
GlaxoSmithKline formed through the merger of Glaxo Wellcome and SmithKline Beecham.
1.6 DEVELOPMENT OF THE COMPANY
GlaxoSmithKline plc is a public limited company incorporated on 6th December 1999 under
English law. Its shares are listed on the London Stock Exchange and the New York Stock
Exchange. On 27th December 2000 the company acquired Glaxo Wellcome plc and SmithKline
Beecham plc, both English public limited companies, by way of a scheme of arrangement for the
merger of the two companies. Both Glaxo Wellcome and SmithKline Beecham were major
global healthcare businesses.
GSK plc and its subsidiary and associated undertakings constitute a major global healthcare
group engaged in the creation, discovery, development, manufacture and marketing of
pharmaceutical and consumer health-related products.
GSK has its corporate head office in London. It also has operational headquarters in Philadelphia
and Research Triangle Park, USA, and operations in some 114 countries, with products sold in
over 140 countries. The principal research and development (R&D) facilities are in the UK, the
USA, Belgium, Italy, Japan and Spain. Products are currently manufactured in some 38
countries. The major markets for the Group’s products are the USA, France, Japan, the UK,
Italy, Germany and Spain.
BANGALORE INSITUTE OF MANAGEMENT STUDIES Page 10
AN ORGANIZATION STUDY
1.7 ORGANIZATION AWARDS
Business in the community award
Awards for diversity and our community work.
Corporate equality, US Human Rights Campaign Foundation
Best diversity company
Diversity and equal treatment
Business champion
Energy management through resilience and mental wellbeing
Most socially responsible company
Most family friendly company
Achieving significant milestones in leadership initiative
Global Super Achiever award
Excellence Through People standard
Supporting the local community
World-class health and safety excellence awards.
Gold H.E.A.L.T.H award
CEO cancer gold standard
Best employers for healthy lifestyle gold award
Unique workplace ergonomics
Helping employees recognize health and performance links
Awards for excellence 2007
BANGALORE INSITUTE OF MANAGEMENT STUDIES Page 11
AN ORGANIZATION STUDY
1.8 PRODUCTS OF THE COMPANY
MEDICINES
GSK pharmaceutical products include treatments for asthma, HIV/AIDS, malaria, depression, migraine, diabetes, heart failure, digestive conditions and cancer.
GSK top selling products in 2007 are designed to treat:
Asthma , Epilepsy ,Diabetes , Herpes ,Migraine
LIST OF MEDICINES
Adartrel, Advair, Albenza, Alkeran, Altargo, Amerge, Amoxil, Andropatch, Anectine, Arixtra, Argatroban, Arixtra, Arranon, Atriance, Augmentine, Avandamet, Avandaryl, Avandia, Avodart, Axid
Bactroban, Becloforte, Becodisks, Beconase, Becatide, Betnovate, Benxor, Boniva
Ceftin, Cicatrin, Combivir, Coreg, Coreg CR, Cutivate
Daraprim, Dermovate, Dexedrine, Digibind, Doralese Tiltabs, Dyazide, DynaCirc CR
Efcortelan, Epivir, Epzicom, Eumavate
Flixonase, Flixotide, Flolan, Flonase, Flovent, Fortaz, Fortum
Hycamtin
Imigran, Imitrex, Imuran, Innopran XL, Integrilin
Kemadrin, Kivera
Lamictal, Lanaxin, Lanvis, Leukeran, Leniva, Liskonum, Lovaza
BANGALORE INSITUTE OF MANAGEMENT STUDIES Page 12
AN ORGANIZATION STUDY
Malarone, Mepron, Mivacron, Myleran
Naramig, Nimbex
Otosporim,
Parnate, Panil, Pentostam, Puri-Nethal, Pylorid
Relafen, Relenza, Requip, Respontin, Retrovir, Rythmol, Rythmol SR
Septrin, Seretide, Serevent, Seroxat,
Tabloid, Tagament, Telzir, Timentin, Tracrium, Trenimet, Trimovate, Trizivir, Tykerb, Tyverb
Ultiva,
Valtrex, Ventodisks, Ventolin, Veramyst, Volibris, Volman,
Welbutrin, Welvone,
Zantac, Zeffix, Ziagen, Zinacef, Zinnat, Zafran, Zoviran, Zyban, Zyloric ETC.
VACCINES
GSK make over 30 vaccines that protect against a wide range of diseases including:
Cervical Cancer, Diphtheria ,Hepatitis A and B , Influenza Meningitis, Polio, Rotavirus,
Whooping Cough
BANGALORE INSITUTE OF MANAGEMENT STUDIES Page 13
AN ORGANIZATION STUDY
LIST OF VACCINES
A C W Y Vax, Ambirix, Bootrix, Cerarix, Engerix, Fendrix, Fluarix, Flulaval, Havrix, Heptyrix,
Hiberix, Infanrix, Infanrix IPV, Infanrix IPV+Hib, Kinrix, Menitorix, Pediarix, Poliomyelitis,
Priorix, Rotarix, Twinrix, Typherix, Varilirix ETC.
CONSUMER HEALTHCARE BRANDS
GSK bring dental health products, over-the-counter medicines and nutritional drinks to millions
of people. Many of our brands, such as Panadol,
Aquafresh, and Lucozade are
familiar around the
world.
LIST OF CONSUMER HEALTHCARE BRANDS :
Abreva, Abtei, Alli, Alluna, Aquafresh, Astriginsol.
BC Powder, Beano, Beechams, Breath Right
Cetebe, Chap-et, Chlorhexamed, Cholinex, Coldrex,
Citrucel, Commit Lozenge, Committed Quitters, Contac,
Corega, Corsadyl, Cortal, Crocin
Debrox, Dequadin, Dr. Best
Ecotrin, Eno, Eumovate, Eunova
Fenbid, Feosol, Fiber Choice, Flinonose Allergy, Formigran,
BANGALORE INSITUTE OF MANAGEMENT STUDIES Page 14
AN ORGANIZATION STUDY
Gaviscon,Gerital, Gly-Oxide, Goody’s Powder, Granufink
Hibitane, Hinds, Horlicks
Imigran Recovery, Insto, Ioden, Iodoson
Lactacyd, Libenar, Lucozade,
Mac cleans, Mactava, Massengill, Medacalm, Mejoral
NiQuitin, Nicoderm CQ, Nicabate, Nicorette, Nytal
Oasis, Odal, Odal-Med 3, Os-cal
Panadeine, Panadal, Parodontax,
Phazyme, Piriton, Potident, Polident 5
minute, Poligrip Ultra
Ribena, Rutinascorbin
Scatt’s Emulsion, Sensodyne,
Shumitect, Solpdeine, Somiex,
Stanback, Super Poligrip, Super wernet’s, Synthal
Tagamet, Targon,Tums
Valda, Viva, Vivarin
Zontac, Zavirax ETC.
1.9 COMPETITORS
MEDICINES
The pharmaceutical industry is highly competitive. GlaxoSmithKline believes that its
competitive position is dependent upon the discovery and development of new products, together
with effective marketing of existing products. Within the pharmaceutical industry, the
BANGALORE INSITUTE OF MANAGEMENT STUDIES Page 15
AN ORGANIZATION STUDY
introduction of new products and processes by competitors may affect pricing levels or result in
product replacement, and there can be no assurance that GlaxoSmithKline’s products may not
become outmoded, notwithstanding patent or trademark protection. In addition, increasing
government and other pressure for physicians and patients to use generic pharmaceuticals rather
than brand-name medicines may increase competition for products that have gone off patent.
VACCINES
GlaxoSmithKline’s major competitors in the vaccine market include Aventis Pasteur, Merck and
American Home Products. Engerix-B and Havrix compete with vaccines produced by Merck –
Comvax and Recombivax HB for hepatitis B and Vaqta for hepatitis A. Infanrix’s major
competitors are Aventis Pasteur’s Tripedia and TriHIBit, and Wyeth Ayerst’s Acel-Imune and
Tetramune.
CONSUMER HEALTHCARE
The major competitors in the consumer healthcare markets are Procter & Gamble, Colgate-
Palmolive, American Home Products, Unilever and Johnson & Johnson.
In the USA, the major competitor products in OTC medicines are: Tylenol Cold (cold remedy),
Clearasil (acne treatment), Pepcid (indigestion) and private label in smoking cessation. In the UK
the major competitor products are: Lemsip (cold remedy), Nurofen and Anadin (analgesics) and
Nicotinell (smoking cessation remedy).
In nutritional healthcare the major competitors to Horlicks are Ovaltine and Milo malted food
and chocolate drinks. The competitors to Ribena are primarily local fruit juice companies while
Lucozade competes with other energy drinks.
BANGALORE INSITUTE OF MANAGEMENT STUDIES Page 16
AN ORGANIZATION STUDY
COMPETITOR’s CHART
GSK VS INDUSTRY LEADERS
Statistic Industry Leader GSK GSK Rank Market Capitalization JNJ 186.73B 125.67B 3/31P/E Ratio (ttm) APP 119.25 13.2 11 /31
BANGALORE INSITUTE OF MANAGEMENT STUDIES Page 17
AN ORGANIZATION STUDY
XPEG Ratio (ttm, 5 yr expected) AZN 5.19 3.1 3/31Revenue Growth (Qtrly YoY) KERX 373.80% 1.70% 15/31EPS Growth (Qtrly YoY) LLY 108.40% -9.40% 10/31Long-Term Growth Rate (5 yr) WX 35.19% 4% 13/31Return on Equity (ttm) GSK 53.12% - 1/31Long-Term Debt/Equity (mrq) GSK 1.112 - 1/31Dividend Yield (annual) PFE 7.10% 4.30% 3/31
BANGALORE INSITUTE OF MANAGEMENT STUDIES Page 18
AN ORGANIZATION STUDY
CHAPTER – II
ORGANIZATION STRUCTURE
(HIERARCHY)
2.1 ORGANIZATION MANAGEMENT
GSK Company is managed by the Board of Directors and the Corporate Executive Team.
BANGALORE INSITUTE OF MANAGEMENT STUDIES Page 19
AN ORGANIZATION STUDY
The Board is comprised of five executive and 11 non-executive directors who are responsible for our corporate governance and ultimately accountable for our activities, strategy and performance.
The Chief Executive Officer (CEO) is responsible for the management of the business and is assisted by the Corporate Executive Team that manages our activities. Each member is responsible for a specific part of the business.
BOARDS OF DIRECTORS
The Board of Directors is responsible for GSK Company's corporate governance and ultimately accountable for our activities, strategy and performance.
NAME OF BOARD OF DIRECTORS
Sir Christopher Gent - Non-Executive Chairman
Andrew Witty - Chief Executive Officer
Professor Sir Roy Anderson - Non-Executive Director
Dr Stephanie Burns - Non-Executive Director
Lawrence Culp - Non-Executive Director
Sir Crispin Davis - Non-Executive Director
Julian Heslop - Chief Financial Officer
Sir Deryck Maughan - Non-Executive Director
Dr Daniel Podolsky - Non-Executive Director
Sir Ian Prosser - Senior Independent Non-Executive Director
Dr Ronaldo Schmitz - Non-Executive Director
Moncef Slaoui - Chairman, Research & Development
Tom de Swaan - Non-Executive Director
Chris Viehbacher - President, North American Pharmaceuticals
Sir Robert Wilson - Non-Executive Director
MEMBERSHIP OF BOARD COMMITTEES IS INDICATED IN THE TABLE BELOW
BANGALORE INSITUTE OF MANAGEMENT STUDIES Page 20
AN ORGANIZATION STUDY
Audit
CorporateAdministration
& Transactions
Corporate Responsibility
Financial Results
Nominations
Remuneration
Gent M C M C MWitty M M
Anderson M MBurns M M MCulp M M MDavis M M M
De Swaan C M M MHeslop M M
Maughan M M MPodolsky M M M MProsser M M M M MSchmitz M M M M MSlaoui M M
Viehbacher M M
Wilson M M M C
Key : C = Chairman M = Member
CORPORATE EXECUTIVE TEAM
The Chief Executive Officer is responsible for the management of the business and is assisted by the Corporate Executive Team.
Andrew Witty - Chief Executive Officer
Simon Bicknell - Senior Vice President, Company Secretary & Compliance Officer
John Clarke - President, Consumer Healthcare
Marc Dunoyer - President, Asia Pacific/Japan
Eddie Gray - President, Pharmaceuticals Europe
Julian Heslop - Chief Financial Officer
Abbas Hussain - President, Emerging Markets
Duncan Learmouth - Senior Vice President, Corporate Communications and Community Partnerships
Bill Louv - Chief Information Officer
Dan Phelan - Chief of Staff
BANGALORE INSITUTE OF MANAGEMENT STUDIES Page 21
AN ORGANIZATION STUDY
David Pulman - President, Global Manufacturing and Supply
David Redfern - Chief Strategy Officer
Moncef Slaoui - Chairman, Research & Development
Jean Stéphenne - President and General Manager, Biological
Claire Thomas - Senior Vice President, Human Resources
Chris Viehbacher - President, North American Pharmaceuticals
Bob Ingram - Vice Chairman, Pharmaceuticals
ORGANIZATION STRUCTURE
2.2 GSK’S MANAGEMENT IN INDIA
BOARD OF DIRECTORS
D.S. Parekh - Chairman & Independent Director
BANGALORE INSITUTE OF MANAGEMENT STUDIES Page 22
AN ORGANIZATION STUDY
V. Thyagarajan - Vice-Chairman & Non - Executive Director
Dr. H. B. Joshipura - Managing Director
P. Bains - Non-Executive Director
R. R. Bajaaj - Independent Director
Dr. A. Banerjee - Executive Director - Technical
M.B. Kapadia - Senior Executive Director
N. Kaviratne - Independent Director
P.V. Nayak - Independent Director
V. Narayanan - Independent Director
Dr. M. Reilly - Non-Executive Director
R. Sequeira - Executive Director - Human Resources
MANAGEMENT TEAM
Dr. H. B. Joshipura - Chairman
M.B. Kapadia - Senior Executive Director
Dr. A. Banerjee - Executive Director - Technical
R. Sequeira - Executive Director - Human Resources
H. Singh - E.V. P - Pharmaceuticals
M. K. Vasanth Kumar - E.V.P. - Information Technology & Supply Chain
Dr. S. Joglekar - V.P. - Medical & Clinical Research
S. Khanna - V.P. - Finance
R. Limaye - V.P. - Marketing & Commercial Strategy
S. Patel - V.P. - Legal & Corporate Affairs
S. Rajan - General Manager - Corporate Communications
BANGALORE INSITUTE OF MANAGEMENT STUDIES Page 23
AN ORGANIZATION STUDY
BANGALORE INSITUTE OF MANAGEMENT STUDIES Page 24
AN ORGANIZATION STUDY
CHAPTER –III
FUNCTIONAL DEPARTMENTS
(DIVISION)
3.1 FINANCE DEPARTMENT
BANGALORE INSITUTE OF MANAGEMENT STUDIES Page 25
AN ORGANIZATION STUDY
Finance is the lifeblood & backbone of any organization without this any organization cannot
undertake any activities concerning the organization. This is fascinating subject, who deals with
end result, and these end result are measurable in terms of money. It is dynamic and changing.
Finance deals with all the fact of business production, sales, purchasing, and personnel etc. This
has to be managed actually to yield long-term results. Finance necessary is accumulated for the
starting of company and then at a later stage is allocated to all the facts of the business as
mentioned above as per requirement specified in the financial policy.
No organization can function without capital. It is one of the most important resource of an
organization but this financial resource is scare and each organization must make the option use
of the firms at its disposal, the finance department has an important and vital task of arranging
funds and putting them to best use so as to achieve maximum return and improve the profitability
of the organization.
HIERARCHY OF FINANCE DEPARTMENT
G.M.F: GENERAL MANAGER OF FINANCE
F.M : FINANCE MANAGER ASST.F.M. : ASSISTANT FINANCE MANGER
THE MAJOR FUNCTIONS OF THE DEPARTMENT
Financial budgeting, timely allocation of funds
BANGALORE INSITUTE OF MANAGEMENT STUDIES Page 26
G.M.F
F.M F.M
Asst. F.M Asst. F.M Asst. F.M Asst. F.M
Accountant Accountant
AN ORGANIZATION STUDY
Maintenance of records required by the different departments.
Payment of wages and salaries.
Payment of bills
Preparation of Final accounts & annuls reports
FINANCIAL STATEMENT
INCOME STATEMENT
2007 2006
£m £m
Turnover 22,716 23,225
Cost of sales (5,317) (5,010)
Gross profit 17,399 18,215
Selling, general and administration (6,954) (7,257)
Research and development (3,327) (3,457)
Other operating income 475 307
Operating profit 7,593 7,808
Finance income 262 287
Finance costs (453) (352)
Share of after tax profits of associates and joint ventures 50 56
Profit before taxation 7,452 7,799
Taxation (2,142) (2,301)
Profit after taxation for the year 5,310 5,498
Profit attributable to minority interests 96 109
Profit attributable to shareholders 5,214 5,389
5,310 5,498
Basic earnings per share (pence) 94.4p 95.5p
Diluted earnings per share (pence) 93.7p 94.5p
BALANCE SHEET 2007 2006
£m £m Non-current assets
BANGALORE INSITUTE OF MANAGEMENT STUDIES Page 27
AN ORGANIZATION STUDY
Property, plant and equipment 7,821 6,930Goodwill 1,370 758Other intangible assets 4,456 3,293Investments in associates and joint ventures 329 295Other investments 517 441Deferred tax assets 2,196 2,123Derivative financial instruments 1 113Other non-current asset 687 608
Total non-current assets 17,377 14,561
Current assetsInventories 3,062 2,437Current tax recoverable 58 186Trade and other receivable 5,495 5,237Derivative financial instruments 475 80Liquid investments 1,153 1,035Cash and cash equivalents 3,379 2,005Assets held for sale 4 12
Total current assets 13,626 10,992
Total assets 31,003 25,553
Current liabilitiesShort-term borrowings (3,504) (718)Trade and other payables (4,861) (4,831)Derivative financial instruments (262) (40)Current tax payable (826) (621)Short-term provisions (892) (1,055)
Total current liabilities (10,345) (7,265)
Non-current liabilitiesLong-term borrowings (7,067) (4,772)Deferred tax liabilities (887) (595)Pensions and other post-employment benefits (1,383) (2,339)Other provisions (1,035) (528)ivative financial instruments (8) (60)Other non-current liabilities (368) (346)
Total non-current liabilities (10,748) (8,640)
Total liabilities (21,093) (15,905)
Net assets 9,910 9,648
EquityShare capital 1,503 1,498Share premium account 1,266 858Retained earnings 6,475 6,965Other reserves 359 65
Shareholders’ equity 9,603 9,386
Minority interests 307 262
Total equity 9,910 9,648
CASH FLOW STATEMENT 2007( £m) 2006(£m)
Cash flow from operating activities
BANGALORE INSITUTE OF MANAGEMENT STUDIES Page 28
AN ORGANIZATION STUDY
Cash generated from operations 8,080 8,203 Taxation paid (1,919) (3,846) Net cash inflow from operating activities 6,161 4,357 Cash flow from investing activitiesPurchase of property, plant and equipment (1,516) (1,366) Proceeds from sale of property, plant and equipment 35 43 Proceeds from sale of intangible assets 9 175 Purchase of intangible assets (627) (224) Purchase of equity investments (186) (57) Proceeds from sale of equity investments 45 32 Share transactions with minority shareholder – (157)Purchase of businesses, net of cash acquired (1,027) (273) Disposal of businesses and interest in associates – 5 Investments in associates and joint ventures (1) (13) Interest received 247 299 Dividends from associates and joint ventures 12 15 Net cash outflow from investing activities (3,009) (1,521) Cash flow from financing activities(Increase)/decrease in liquid investments (39) (55) Proceeds from own shares for employee share options 116 151 Shares acquired by ESOP Trusts (26) – Issue of share capital 417 316 Purchase of own shares for cancellation (213) – Purchase of Treasury shares (3,538) (1,348) Increase in long-term loans 3,483 – Repayment of long-term loans (207) – Net increase in/(repayment of) short-term loans 1,632 (739) Net repayment of obligations under finance lea (39) (34) Interest paid (378) (414) Dividends paid to shareholders (2,793) (2,598) Dividends paid to minority interests (77) (87) Other financing cash flows (79) 16 Net cash outflow from financing activities (1,741) (4,792) Increase/(decrease) in cash and bank overdrafts 1,411 (1,956) Exchange adjustments 48 (254) Cash and bank overdrafts at beginning of year 1,762 3,972 Cash and bank overdrafts at end of year 3,221 1,762 Cash and bank overdrafts at end of year comprise:Cash and cash equivalents 3,379 2,005 Overdrafts (158) (243) 3,221 1,762
STATEMENT OF RECOGNISED INCOME AND EXPENSE
BANGALORE INSITUTE OF MANAGEMENT STUDIES Page 29
AN ORGANIZATION STUDY
Exchange movements on overseas net assets 425 (390)
Tax on exchange movements 21 (78)
Fair value movements on available-for-sale investments (99) 84
Deferred tax on fair value movements on available-for-sale investments 19 (15)
Exchange movements on goodwill in reserves (14) 31
Actuarial gains/(losses) on defined benefit plans 671 429
Deferred tax on actuarial movements in defined benefit plans (195) (161)
Fair value movements on cash flow hedges ( 6) (5)
Deferred tax on fair value movements on cash flow hedges 2 2
Net profits/(losses) recognised directly in equity 824 (103)
Profit for the year 5,310 5,498
Total recognised income and expense for the year 6,134 5,395
Total recognised income and expense for the year attributable to:
Shareholders 6,012 5,307
Minority interests 122 88
6,134 5,395
NOTE ON FINANCIAL STATEMENT
DESCRIPTION OF BUSINESS
GlaxoSmithKline is a major global healthcare group which is engaged in the creation and
discovery, development, manufacture and marketing of pharmaceutical products including
vaccines, over-thecounter (OTC) medicines and health-related consumer products. GSK’s
principal pharmaceutical products include medicines in the following therapeutic areas:
respiratory, central nervous system, anti-virals, anti-bacterials, metabolic, vaccines,
cardiovascular and urogenital, anti-bacterial, oncology and emesis.
COMPOSITION OF FINANCIAL STATEMENTS
The financial statements are drawn up in Sterling, the functional currency of GlaxoSmithKline
plc, and in accordance with IFRS accounting presentation. The financial statements comprise:
• income statement
• balance sheet
BANGALORE INSITUTE OF MANAGEMENT STUDIES Page 30
AN ORGANIZATION STUDY
•cash flow statement
•statement of recognized income and expense
ACCOUNTING CONVENTION The financial statements have been prepared using the historical cost convention, as modified by
the revaluation of certain items, as stated in the accounting policies.
ACCOUNTING POLICIES
Financial statements include:
The assets and liabilities, and the results and cash flows, of the company and its
subsidiaries, including ESOP Trusts
The Group’s share of the results and net assets of associates and joint ventures.
Foreign currency translation
Revenue
Expenditure
Research and development
Environmental expenditure
Legal and other disputes
Pensions and other post-employment benefits
Employee share plans
Property, plant and equipment
Leases
Goodwill
Other intangible assets
Impairment of non-current assets
Investments in associates and joint ventures
Available-for-sale investments
Inventories
Trade receivables
Trade payables
Cash and cash equivalents
Taxation
BANGALORE INSITUTE OF MANAGEMENT STUDIES Page 31
AN ORGANIZATION STUDY
Derivative financial instruments and hedging
Discounting
PAYMENT POLICIES
Group companies are responsible for monitoring and managing their working capital. The
terms of sales collections and supplier payments reflect local commercial practice.In the
UK, the company and each of its UK subsidiaries have policies to ensure that suppliers
are paid on time. In particular, the UK companies seek:
to settle terms of payment with suppliers when agreeing the terms of the transaction
to ensure that suppliers are made aware of the agreed terms of payment
to abide by the terms of payment.
The policy includes arrangements for accelerated payment of small suppliers.
2007 PERFORMANCE OVERVIEW
Turnover, business performance* earnings perTurnover, business performance* earnings pershare growth and total shareholder return return
THIS GRAPH SHOWS ANNUAL TURNOVER OF GSK
BANGALORE INSITUTE OF MANAGEMENT STUDIES Page 32
AN ORGANIZATION STUDY
THIS GRAPH SHOWS EARNING PER SHARE OF GSK
Earnings per share have been calculated by dividing the profit attributable to shareholders by the weighted average number of shares in issue during the period after deducting shares held by the ESOP Trusts and Treasury shares.
THIS GRAPH SHOWS TOTAL SHAREHOLDER RETURN OF GSK
BANGALORE INSITUTE OF MANAGEMENT STUDIES Page 33
AN ORGANIZATION STUDY
THIS GRAPH SHOWS SHARE PRICE OF GSK
The graph sets out the middle market closing prices derived from the London Stock Exchange
Daily Official List. The company’s share price decreased by 5% in 2007 from a price of £13.44
at 1st January 2007 to £12.79 at 31st December 2007. This compares with an increase in the
FTSE 100 index of 4% during the year. The share price on 22nd February 2008 was £11.10.
BANGALORE INSITUTE OF MANAGEMENT STUDIES Page 34
AN ORGANIZATION STUDY
3.2 HUMAN RESOURCE DEPARTMENT
Human resource department plays an important role in any organization. There so many
functions deployed in the organization which will coordinates the employees in the organization
and achieve the organizational goals.
HIERARCHY OF HUMAN RESOURCE DEPARTMENT
HR DEPARTMENT IN GSK
GSK employs over 100,000 people in 119 countries.
In GSK HR department is a very important and clearly defined department. The department
performs the personnel and administrative functions. It has a direct link with the employees and
understands their needs and wants.
R. Sequeira is the Executive Director and he looks after all the human elements of the
organization. This department deals with the effective and efficient control and use of manpower
as differently from other sources of power..
BANGALORE INSITUTE OF MANAGEMENT STUDIES Page 35
HR HEAD
PERSONAL
MANAGER
HR EXECUTIVE
AN ORGANIZATION STUDY
PLANNING
Human resource or manpower planning is the process by which a management determines how
an organization should move from its current manpower position.
Through planning, a management strives to have the right number and the right kinds of people
at the right places, at the right time, to do things which result in both the organization and the
individual receiving the maximum long range benefit.
RECRUITMENT PROCESS
First the bio-data is collected from the prospective worker.
The P.M. interviews him/her then, interviews are conducted on the basis of which
section he is going to be placed.
His experience is also taken into consideration.
If he has all the technical qualification, a declaration letter will be given to him/her.
If there are unskilled employees, they are first appointed as helpers.
BANGALORE INSITUTE OF MANAGEMENT STUDIES Page 36
AN ORGANIZATION STUDY
TRAINING
Training means to give information or skill through instructions or practical. It is a method for
increasing the knowledge and skill of the people for a specific job. “Training is the art of
increasing the knowledge and skills of employees for doing a particular job”.
THE TRAINING METHODS ARE:-
ON THE JOB TRANING
This is a common used method for training the operative personnel. The workers are trained
under the same type of conditions they have to work in future. On the job he can experience the
conditions and requirements of actual work situations.
OFF THE JOB TRAINING
Off the job training generally consists of conferences, seminars, lectures, group discussions, case
studies, programmers, instructions etc.
APPRENTICESHIP TRAINING
In apprenticeship training a worker is appointed as an apprentice. The company gives
apprenticeship training in the following trades: Electrical, Plumber, Fitting
For selection or incumbent in cash trade, company seeks the list from the regional trainingcentre,
as per the rules.
REMUNERATION TO EMPLOYEES
The minority reward paid by the management to worker or an employee for the performance of
the assigned task is called “wages” or “salary”. Salary is the remuneration paid to non-operative
staff: salaries are paid on a monthly basis to office staff, managers and Technical advisors etc.
Wages is the remuneration paid to the workers involved in production. Work and who’s output
can be directly measured.
BANGALORE INSITUTE OF MANAGEMENT STUDIES Page 37
AN ORGANIZATION STUDY
PERFORMANCE AND REWARD
Reward systems are designed to support a culture of high performance and to attract and retain
the best people. Performance based pay and bonuses, share awards and share options align
employee interests with the meeting of business targets
GSK Employment Awards
GSK receives Top Honours from NBGH for Providing Healthy Workplace and Promoting
Healthy Lifestyles 2008
Britain's Top Employers 2008
Top companies for leaders 2007
16 years on the Working Mother 100 best companies list
Employer of choice for Research and Development
The most effective use of workplace financial education
Britain's top employers 2007, 4th place
Best places to work for industry award, 9th place
Top 10 most respected/best employers
Leaders employment learning innovations award, top 20
One of the top 50 best companies to work for in Ireland
Vietnam's 50 best employers for 2006
Top 50 employer
Best practices, employer of choice, HR and diversity excellence
National graduate recruitment awards, 3rd place
Best in class in Engineering and Science for graduates
Times Top 100 graduate recruiters 2007, 13th place
Most popular graduate recruiter in Engineering and Science
GSK Poland "friendly employer"
GSK Poland "women friendly employer
GSK Finland "great place to work", 6th place
BANGALORE INSITUTE OF MANAGEMENT STUDIES Page 38
AN ORGANIZATION STUDY
SALARY MODEL
BASE SALARYBase salaries are set by reference to the median for the relevant market. For Executives, this is
the pharmaceutical pay comparator group. Actual salary levels are reviewed annually and are
influenced by an Executive’s experience, responsibility and market value
ANNUAL BONUS
All annual cash bonuses are determined on the basis of a formal review of annual performance
against stretching financial targets based on profit before interest and tax and are subject to
detailed assessment of individual, business unit and Group achievements against objectives. No
bonus is payable if financial performance
is less than 96% of the target.
LONG-TERM INCENTIVESExecutives are eligible for annual long-term incentive (LTI) awards, and the remuneration policy
provides that these will normally be made up of a performance share award and a share option
award.
RELATIONS BETWEEN MANAGEMENT AND UNION
Most of the employee’s opinion is that there is a healthy relationship between the management
and union. So the management must take necessary steps to maintain this good relationship. So
there is no problem from the part of the union.
BANGALORE INSITUTE OF MANAGEMENT STUDIES Page 39
AN ORGANIZATION STUDY
3.3 MARKETING DEPARTMENT
Marketing department is largely concerned with building customer satisfaction through quality
sales. Marketing department managers manage the marketing process and plan time-to-time
market research at the time of analyzing the market environment and customer behavior.
To achieve standards, efforts are made to satisfy the customer. To earn the trust of every
probable customer, locally or globally the company maintains high quality all times. For
attaining peak professionalism sales person are trained and organized by the department to
achieve organizational objectives.
HIERARCHY OF MARKETING DEPARTMENT
G.M.M : GENERAL MANAGER OF MARKETING
R.B.M : REGIONAL BUSINESS MANAGER
A.B.M : AREA BUSINESS MANAGER
M.R : MEDICAL REPRESENTATIVE
BANGALORE INSITUTE OF MANAGEMENT STUDIES Page 40
G.M.M
R.B.M R.B.M
A.B.M A.B.M A.B.MA.B.M A.B.M A.B.M A.B.M A.B.M
22 M.R 12 M.R 8 M.R10 M.R 6 M.R26 M.R 8 M.R 5 M.R
AN ORGANIZATION STUDY
FUNCTIONS OF MARKETING DEPARTMENT
This department prepares an annual marketing plan and sales forecast.
It works with advertisements and sales promotion.
It looks after the customer services.
Marketing manager stimulates the support of product among the sales force and distributors.
Initiating product improvements to meet changing market needs is one of the functions of
this department.
This department gathers continuous intelligence on the product’s performance, customer and
dealer attitudes and new problems and opportunities.
Conducting a market research, developing long range and competitive strategy for the
products.
Prepares annual marketing plan and sales forecast.
Advertisement and sales promotion.
Look after customer services.
Initiating product improvement.
Marketing research.
MARKETING ETHICS
GSK market our medicines to doctors, hospitals and governments. In some countries, such as
the US, we also advertise medicines directly to consumers. Our specialist sales
representatives meet regularly with doctors and pharmacists to inform them about our
medicines and their approved uses.
GSK believe that sales representatives play an important role inproviding up-to-date
information to doctors on our products and their benefits to patients. However, we recognise
that the marketing of pharmaceutical products raises some challenging issues.
In particular, some people are concerned that marketing by pharmaceutical companies exerts
undue influence on doctors, that sales representatives do not always give doctors full
BANGALORE INSITUTE OF MANAGEMENT STUDIES Page 41
AN ORGANIZATION STUDY
information about potential side effects, or that promotion for unapproved uses may be
occurring despite increased training, monitoring and oversight.
GSK approach to addressing these issues includes regional marketing codes of practice,
regular training and monitoring.
GSK FOLLOWS RECOGNIZATION MARKETING CODES
Variations in these codes relate to differences in market structure, national healthcare systems
and underlying laws and regulations than to a difference in our ethical approach to market
behaviour.
In the United States, GSK abides by the PhRMA Code on Interactions with Healthcare
Professionals and the PhRMA Guiding Principles on Direct-to-Consumer Advertisements
of Prescription Medicines. GSK also has in place a set of “Commercial Practices
Policies” that were developed to provide clear rules on how GSK employees should
conduct themselves in their job. Included in those are policies that govern 16 specific
promotional and educational activities.
In Europe, GSK observes individual country laws, regulations and industry codes,
including the European Federation of Pharmaceutical Industries and Associations
(EFPIA) Code of Practice and has its own GSK European Promotion of Medicines Code
of Practice.
Across our International Region, GSK has an International Pharmaceuticals Promotion
& Marketing Code designed to ensure a consistent framework for in-country sales and
marketing activity. The code is based on IFPMA Guidelines, and applies to all 118
countries in the GSK International Area. In addition, individual country businesses
frequently have codes that reflect the specific laws and regulations of the countries in
which they operate.
BANGALORE INSITUTE OF MANAGEMENT STUDIES Page 42
AN ORGANIZATION STUDY
In Japan, GSK has a separate and distinct Code that is based on both the Japan
Pharmaceutical Manufacturer’s Association (JPMA) Marketing Code and IFPMA Code
Guidelines.
TRAINING AND AWARENESS
Over 14,000 managers completed our self certification process in 2007. Other training and
awareness initiatives vary from region to region and included:
11,000 sales and marketing staff in our international region received training on our
revised Pharmaceuticals International Promotion and Marketing Code
831 US field sales managers and 228 marketing staff (the employees responsible for
overseeing sales representatives) attended our new Compliance University programme at
venues across the US. The programme provided a half day interactive course on key
compliance areas. Senior managers and compliance officers also attended to answer
questions from attendees, help them to explore potential ethical dilemmas and reinforce
the importance of the subjects covered
Country compliance officers and contacts in Europe received training on topics such as
key corporate policies, ethical dilemmas, and records management
Targeted communication and training for R&D employees who engage with external
experts (including healthcare professionals). This included e-learning modules covering
use of external experts and payments to healthcare professionals and the provision of
gifts
Launched a coaching excellence programme in GSK Biologicals to help new employees
understand and adopt GSK values and develop their skills
Annual online promotion compliance training for all GSK Japan employees who meet
with healthcare professionals.
Every two years we conduct a leadership survey of GSK managers. The last survey in 2006
showed that 91 per cent of GSK managers believe ‘people in my department show commitment
to performance with integrity.’ 76 per cent agreed with the statement that ‘I can report unethical
practices without fear of reprisal’, considerably higher than the overall industry benchmark of 68
per cent.
BANGALORE INSITUTE OF MANAGEMENT STUDIES Page 43
AN ORGANIZATION STUDY
REGIONAL ANALYSIS
Pharmaceutical turnover by geographic region in 2007 on an invoiced basis The turnover
reported in the table below represents sales invoiced by GSK’s local entity to its customers in the
local market plus copromotion income within each market
BANGALORE INSITUTE OF MANAGEMENT STUDIES Page 44
AN ORGANIZATION STUDY
THIS GRAPH SHOWS SALES AND CONSTANT EXCHANCE RATE GROWTH BY REGION OF GSK
BANGALORE INSITUTE OF MANAGEMENT STUDIES Page 45
AN ORGANIZATION STUDY
3.4 PRODUCTION DEPARTMENT
GSK’s manufacturing operations comprise a network of 79 sites in 37 countries and employ over 33,000 people.GSK manufactures a large portfolio of products, ranging from tablets and toothpaste to inhalers
and complex capsules, in over 28,000 different pack sizes and presentations. Manufacture of
medicines starts with the development of atherapeutic active ingredient (bulk active) in a
selected formulation. Global Manufacturing and Supply (GMS) develops manufacturing
processes for full scale volume production of active compounds at primary manufacturing sites.
Secondary sites then convert these active compounds into finished medicines. Each year GMS
produces around 6,000 tonnes of bulk actives and more than four billion packs, which are sold in
over 140 countries. It also supports about 2,000 new product and line extension launches every
year. By adopting leading edge practices and developing its people,
GMS provides:
• a secure source of supply of high quality products
• compliance with regulatory requirements and customer expectations
• best in class cost
THE MAIN FUNCTIONS OF PRODUCTION DEPARTMENT ARE
To meet the raising demand of the consumer.
To provide better quality product and services.
To expand the existing business.
To maintain the factory premises i.e. proper utilization of the available space.
To reach out to the industrial market with increased production and high standards.
BANGALORE INSITUTE OF MANAGEMENT STUDIES Page 46
AN ORGANIZATION STUDY
HIERARCHY OF PRODUCTION DEPARTMENT
BANGALORE INSITUTE OF MANAGEMENT STUDIES Page 47
WORKS MANAGER
SUPERVISOR
ENGINEER
SENIOR ENGINEER
OFFICE ASSISTANT
GENERAL MANAGER OF PRODUCTION
AN ORGANIZATION STUDY
MANUFACTURING OPERATIONS
GSK has 46 manufacturing sites outside Europe and North America including one in an LDC
(Chittagong, Bangladesh). Here we have contracts with 3 companies for the supply of inhaled
aerosol products, penicillin, local solid dose products and Horlicks.
The sites form part of the corporation’s business strategy and were established in response to a
business need or, in
some
BANGALORE INSITUTE OF MANAGEMENT STUDIES Page 48
AN ORGANIZATION STUDY
circumstances, because of local government insistence on “local working” as part of the product
registration process.
GSK production sites in Algeria, Hungary, Morocco, Nigeria, Sri Lanka and Turkey produce for
the domestic market. However, many GSK facilities in developing countries also export to other
parts of the world such as is the case in Argentina, Brazil, Costa Rica, Egypt, India, Indonesia,
Kenya, Malaysia, Mexico, Pakistan, Panama, Philippines and South Africa, By operating these
manufacturing sites, GSK promotes the development of skills and technical expertise of the
workforce in those countries.
GSK also has a programme of “know-how” transfer to local manufacturers whereby we
outsource production of products as part of a carefully managed production cycle aimed at
freeing up GSK production capacity for the development of new drugs and vaccines.
Transfer of production usually occurs post-patent expiry for products which local operating units
consider of strategic and/or commercial importance in local or regional markets. They remain
GSK branded products, sold and marketed by the company; however production is done by a
third party contractor, with the necessary regulatory and technical support from GSK to ensure
compliance with local and international standards.
Horlicks Production
· India: GSK has three Horlicks factories in India dating from 1959, 1973 and 2002 (one in
Punjab in the North, one in Andhra Pradesh in the South, and the third in Haryana, which
commenced production in 2002). Two of the factories - in Punjab (Nabha) and Andhra Pradesh
(Rajahmundry) - buy cow/buffalo milk from around 40,000 local farmers. When we first started
BANGALORE INSITUTE OF MANAGEMENT STUDIES Page 49
AN ORGANIZATION STUDY
operations in India, local farming families agreed to keep additional animals so that they had
surplus milk over and above their family requirements to sell to GSK.
We in turn provide aid in terms of veterinary assistance, subsidised cattle feed,artificial
insemination, free deworming as well as holding training programmes on animal husbandry to
enable the farmers to maximise the output of each animal and enhance the population.
RESEARCH AND DEVELOPMENT (R&D) POLICIES
The R&D process is highly regulated, wherever GSK operates. As scientific advances
raise new issues, we work closely with the regulators, policy makers, and stakeholders to
develop new or refined standards. We have our own internal standards and systems to
ensure that we comply with or exceed guidelines, regulations and legal requirements.
Policies apply to interactions of GSK R&D employees with healthcare professionals or
with the U.S. Government. These Policies cover a range of activities including:
Guidelines for requesting and receiving external consultancy in R&D over a defined
monetary limit
Standards for compensating, reimbursing, and providing financial benefits to healthcare
practitioners , or their affiliated institutions or organizations, conducting GSK-
sponsored or GSK-supported clinical studies.
Standards for determining the need for external experts and for selecting, using,
compensating, and interacting with external experts within GSK R&D
Framework and requirements for managing GSK's procurement, maintenance, and
administration of research funding from agencies of the U.S. Government.
Meals or gift items related to a healthcare professional’s practice
Sponsoring independent medical education or providing charitable contributions
3.5 SYSTEMS DEPARTMENT
System ought to be designed on based on the synergy of subsystem viz. human resource,
production, marketing, sales, logistic, inventory control, manufacturing, legal, finance,
accounting, customer care, and services with interrelation among one another in order to achieve
BANGALORE INSITUTE OF MANAGEMENT STUDIES Page 50
AN ORGANIZATION STUDY
a net unified cohesive system and to achieve organizational objectives. It is the mean of
circulating the information between the various departments of an organization and monitoring
the performance and to carry business practices to serve society efficiently and effectively. It
plays a prominent and crucial role in various subsystem of an organization as discussed below.
MARKETING AND SALES DEPARTMENT
Marketing and sales subsystem generally include all activities related to promotion and sales of
product or services. The transactions are sales order, promotion order, etc. The operational
control activities include hiring and training of the sales force, the day to day scheduling of sales
and promotion efforts, and periodic analysis of sales volume by region, product, customer etc.
Managerial control concerns comparison of overall performance against a marketing plan.
Information for managerial control may include data on customer, competitors, competitor’s
product and sales force requirement. Strategic planning for the marketing function involves
consideration of new market and new marketing strategies. The information requirement for
strategic planning includes customer analysis, compotators analysis, consumer survey
information, income projection, demographic projection and technology projection.
PRODUCTION DEPARTMENT
The responsibilities of production or manufacturing subsystem include product engineering,
planning of production facilities, scheduling and operation of production facilities, employment
and training of production personal, and quality control and inspection. Typical transactions to
be processed are production orders, assembly order, finished part tickets, scrap tickets and time
keeping tickets. Operational control requires detailed reports comparing actual performance to
production schedule and highlight areas where bottleneck occurs. Management control requires
summery reports which compare overall plan or standard performance to actual performance for
such classification as cost per unit and labor used.
HUMAN RESOURCES DEPARTMENT
The human resources subsystem includes hiring, training, record keeping, payment, and
termination of personnel. The transaction result in documents describing employment
BANGALORE INSITUTE OF MANAGEMENT STUDIES Page 51
AN ORGANIZATION STUDY
requisitions, job description, training specification, personal data, pay rate changes, hour worked,
paychecks, benefits and termination notice. Operational control for personal require decision
procedure for action such as hiring, training, termination, changes pay rate and issuing benefits.
Management control of the personal function is supported by reports and analysis showing the
variance resulting from difference of employee hired and actual performance for such
classification as number of employee hired, cost of recruiting, compositions of skill inventory,
cost of training, salary paid, distribution of wage rates, and conformance with government equal
opportunity requirement.
FINANCE AND ACCOUNTING DEPARTMENT
Finance and accounting are somewhat separate functions but are sufficiently related to each
other. Finance subsystem is responsible for ensuring adequate organizational financing at as a
low cost as possible, finance function covers of granting credit to customers, collection process,
cash management and financial arrangements. Accounting covers the classification of financial
transactions and summarization into the standard financial reports (income statement and balance
sheet), the preparation of budget and classification analysis of cost data.
LAN
Local area network (LAN) is a group of computers and associated devices that share a common
communication line or wireless link. Typically connected devices share the resources of a single
processors or server with in small geographic area. Usually the server has application and data
storage that are shared in common by multiple computer users
Major Local Area Network technologies are:
Ethernet
Token Ring
FDDI
WAN
BANGALORE INSITUTE OF MANAGEMENT STUDIES Page 52
AN ORGANIZATION STUDY
Wide area network is geographically dispersed telecommunication network. The term
distinguishes a broader telecommunication structure from a local network. A wide area network
may be privately owned or rented, but the terms usually connote the inclusion of public
networks. An intermediate form of network in terms of geography is a metropolitan area network
TELECONFRERENCING
Teleconferencing means any kind of multi-way communication carried out in real time using
telecommunication or computer networks and equipment
Major teleconferencing technologies are:
Video conferencing
Audio conferencing
Data conferencing
Intranet
E-business requires a network platform, which is seamless and allows smooth flow of data and
information in any form from any location to any other destinations. The intranet essentially any
internal company network that uses standards, namely HTML, HTTP and TCP/IP. The existing
network (LAN/WAN) when loaded with these standards and supported by web server and web
browser becomes Intranet for the organization.
The intranets are used within the organization for the following purposes
Access Manuals, contracts.
Post personal web pages.
Access product, consumer data.
Post job offers, Memos.
Revision, Validation, Approval of documents.
Access databases.
Access schedules, plan, calendars.
Access employee database.
BANGALORE INSITUTE OF MANAGEMENT STUDIES Page 53
AN ORGANIZATION STUDY
Extranet
Intranet is private to the organization; Extranet is an internet for outside authorized user using
same internet technology. The out side users are trusted partners of the organization who have
access to information of their interest and concern
HIERARCHY OF SYSTEM DEPARTMENT
S.M: SYSTEM MANAGER
ASST. S.M.: ASSISTANT SYSTEM MANAGER
The chief of system department is controlled by IT HEAD which has power to control one country under subdivision of four SYSTEM MANAGER which control all four region of the country with the help of ASSISTANT SYSTEM MANAGER.
BANGALORE INSITUTE OF MANAGEMENT STUDIES Page 54
S.M.
IT HEAD
ASST. S.M.
S.M. S.M.
ASST.SM.
S.M.
ASST. S.M. ASST. S.M.
AN ORGANIZATION STUDY
CHAPTER-IV
SWOT ANALYSIS
STRENGTHS:
GSK is the leader not only in terms of Product and Sales but also in terms of corporate
responsibilities with regard to access of medicines.
It has maintained customer loyalty because of quality and brand
BANGALORE INSITUTE OF MANAGEMENT STUDIES Page 55
AN ORGANIZATION STUDY
Approach of GSK is too reactive.
GSK is Market leader for some fast growing and deadly diseases like HIV, TB etc.
GSK is the Sole Company which is
authorized to manufacture medicines
for heart and Brain diseases.
It has maintained market leadership
in industrial sector
Employee satisfaction will be
maintained
WEAKNESS:
GSK has a very passive strategy
It emphasizes its market globally than to Indian market.
High labour turn over
Difficult to maintain the pricing strategies
Difficult to maintain working condition
Training period is less
GSK have no certain goals and strategy
OPPORTUNITIES:
GSK can also foray into food sector.
GSK can be market leader for pharma product.
GSK equally gives importance for range of products as well as quality of the product.
GSK is innovative in nature in terms of manufacturing product instantly.
THREATS
Competition
Government policies
High cost of raw material and labour
Labour availability
Power
BANGALORE INSITUTE OF MANAGEMENT STUDIES Page 56
AN ORGANIZATION STUDY
MISSION
GSK’s mission is to improve the quality of human life by enabling people to do more, fell better
and live longer.
SPIRIT
GSK undertake our quest with the enthusiasm of entrepreneurs excited by the constant search for
innovation we value performance achieved with integrity. We will attain success as a world
class global leader with each and every one of our people contributing with passion and
unmatched senses of urgency.
Business Drivers
GSK face a highly competitive marketplace, populated by other excellent companies, with their
own gifted people, and their own determination to succeed. GSK will beat the competition by
achieving excellence in five areas that are primary drivers for our business.
VISION
GSK vision for the future is powered by their business drivers. It finds purpose and direction
with their strategic intent.
It is guided by our corporate culture that places people and capabilities and the pivot that changes
and transforms situations.
The vision for the future
GlaxoSmithKline’s vision is exciting and will give you the opportunity to make a difference in
the health of billions of people. Our value systems and operating principles will provide the
necessary guide on how we work at GSK. The key to our success will be powered by the desire
and passion to pursue GSK’s priorities, expressed by the business driver
OBJECTIVES OF THE STUDY
BANGALORE INSITUTE OF MANAGEMENT STUDIES Page 57
AN ORGANIZATION STUDY
The general objective of the study is to gain an insight about the functioning of the organization
namely, “GlaxoSmithKline Pharmaceuticals Limited”
The specific objectives of the present study are to:
Study the organization behavior, culture and climate.
Understand the activities and functions of each department.
Know about the availability of GSK’s services.
Carry out the SWOT analysis on the basis of the observation and learning.
Give suggestions and recommendations for improvement of the activities and functions
of the organization.
NEED FOR THE STUDY .
To make M.B.A. program more relevant with respect to the necessities of the corporate or the industries.
To inculcate students practical knowledge of corporate world.
To cover various aspects of general managerial such as organizational structure, functions of respective department in the organization.
SCOPE OF THE STUDY
This study is an attempt to study the organization as a whole and to study the different functional
units in detail so that a detailed knowledge about the organization from different aspects is
gained.
It aims to study the functions of the different departments which constitute the organization so as
to suggest effective changes, so as to help the organization achieve its objectives and the
different departments contribute effectively towards the achievement of this organizational goal.
LIMITATIONS OF THE STUDY
BANGALORE INSITUTE OF MANAGEMENT STUDIES Page 58
AN ORGANIZATION STUDY
It is not possible for any study to make it accurate due to hurdles in collection and
computation of data.
There is no detail information provided, because it is a private company and the Matters are
purely confidential.
Since the Managers are busy with their daily schedules it is not possible for us to spend more
time in interaction and discussion with them.
The major limitation is that the duration allocated for the study is very short. With in two
months the complete organizational study is not possible.
BANGALORE INSITUTE OF MANAGEMENT STUDIES Page 59
AN ORGANIZATION STUDY
CHAPTER-V
SUGGESTIONS AND CONCLUSIONS
SUGGESTIONS OF THE STUDY:
BANGALORE INSITUTE OF MANAGEMENT STUDIES Page 60
AN ORGANIZATION STUDY
GSK has been a leader in promoting access but it was external pressure that led them to this
point
GSK needs to report its goals and strategy
GSK has a very passive strategy – it needs to acknowledge challenges and be more
aggressive in tackling them
Try to make well performance in marketing practices
There is no evidence of alignment between GSK’s CR objectives and public policy.GSK
should be more transparent on this and its lobbying through industry groups
I would like to see really clear goals and targets going forward, especially for access and
R&D.”
Access should be GSK’s priority for the future, in particular finding a balance between
public health and patent protection
CONCLUSIONS OF THE STUDY:
Having read the report I would now use GSK as a best practice example. The work in the
2007 is absolutely excellent.
GSK is a real leader, particularly in research into neglected diseases. They manage to
balance social expectations with business goals
My overall perception is positive. GSK is being pretty ambitious
BANGALORE INSITUTE OF MANAGEMENT STUDIES Page 61
AN ORGANIZATION STUDY
BIBLIOGRAPHY
www.gsk.com
BANGALORE INSITUTE OF MANAGEMENT STUDIES Page 62
AN ORGANIZATION STUDY
www.gsk-india.com
www.nse-ind.com
HUMAN RESOURCE MANAGEMENT K. Ashwatappa
ORGANISATION BEHAVIOUR K. Ashwatappa
BUSINESS MANAGEMENT C.B.Gupta
BANGALORE INSITUTE OF MANAGEMENT STUDIES Page 63